| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 0.0 | 1.2 | 0.0 |
| Other income | 0.0 | 0.1 | 0.0 |
| Total income | 0.0 | 1.2 | 0.0 |
| Profit before exceptional items & tax | -0.3 | 0.6 | -0.0 |
| Profit before tax | -0.3 | 0.6 | -0.0 |
| Net profit | -0.3 | 0.5 | -0.0 |
| Operating margin | 0.0% | 50.0% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Operating profit, quarter on quarter | -160.00% |
|---|
BSE results filing, NSE: COVIDH. Figures extracted from the filing.
iSERA Lifesciences Ltd: key numbers
- Share price
- ₹143.90
- Market cap
- ₹121.0 Cr
- Revenue (annual)
- ₹1.36 Cr
- Net profit (annual)
- ₹0.26 Cr
- P/E (TTM)
- 466.5×Sector 21.8×
- Promoter holding
- 58.63%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from iSERA Lifesciences Ltd
All →iSERA Lifesciences Annual Report
iSERA Lifesciences Limited has submitted its Annual Report for the financial year 2025-26. The 34th Annual General Meeting is scheduled for September 29, 2026.
iSERA Lifesciences Annual General Meeting
iSERA Lifesciences has scheduled its 34th Annual General Meeting for September 29, 2026, and appointed a scrutinizer to oversee the voting process for the event.
iSERA Lifesciences Other Announcement
iSERA Lifesciences filed its Monitoring Agency Report for the Rights Issue proceeds utilization for the quarter ended June 30, 2026.
- Value
- ₹8.08 Cr
iSERA Lifesciences Board Meeting Date
iSERA Lifesciences Ltd scheduled a board meeting for August 7, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.
iSERA Lifesciences Other Announcement
iSERA Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, as per SEBI regulations.
iSERA Lifesciences Annual General Meeting
iSERA Lifesciences issued a corrigendum to its Postal Ballot notice. It clarifies preferential equity share allotments and post-issue capital percentages.